Kymera Therapeutics disclosed novel STAT6 inhibitors in a recent patent publication, broadening its targeted‑protein degradation and small‑molecule portfolio into the STAT transcription factor family. The filing frames applications spanning cancer, inflammatory diseases and metabolic disorders, reflecting STAT6’s role in Th2 immune signalling and tumor biology. The disclosure provides structures and claimed methods of use, underscoring Kymera’s strategy to pursue intracellular signalling nodes with drug‑like small molecules. Given STAT6’s link to allergic and fibrotic pathways, progression of these compounds could attract partnerships or preclinical investment if they show target engagement and selectivity in disease models.